Company intelligence / Profile preview
Alfasigma
Bologna and Pomezia, Italyalfasigma.com ↗
- Ownership
- Private
- Employees
- ~3000
- Development stage
- Commercial
01
Overview
Alfasigma has multiple approved drugs including Ocaliva for primary biliary cholangitis, Filgotinib for ulcerative colitis, Parnaparin Sodium for thrombosis, and several others. The company has expanded its portfolio through acquisitions including Intercept Pharmaceuticals and SOFAR.
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularNeurology
- Modalities
- Small molecule drugsChemical drugsAntibody drug conjugate (ADC)
- Industry
- Biotech
02
Drug pipeline
26 assets25 more assets in the full pipeline.
03
Partnerships
Galapagos (acquired rights to Jyseleca)
Beyond the preview
Go deeper on Alfasigma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alfasigma.